Scholarlink

<p>This predefined subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to determine whether the comparative efficacy and safety of esaxerenone and trichlormethiazide differs with age. Patients were divided into two age subgroups (&lt;65 and ≥65 years). The non-inferiority of esaxerenone to trichlormethiazide was assessed based on the upper limit of the two-sided 95% confidence interval (CI) for the difference in systolic/diastolic blood pressure (SBP/DBP) changes. Esaxerenone was considered non-inferior if this value was &lt;3.9/ &lt; 2.1 mmHg; if it was &lt;0 mmHg, esaxerenone was considered superior in its BP-lowering effect. The results showed that the least squares mean changes in morning home SBP/DBP from baseline to the end of treatment (primary endpoint) were −9.5/−5.7 with esaxerenone and −8.2/−4.9 mmHg with trichloromethiazide (between-group difference: −1.3 [95% CI, −3.3, 0.8]/−0.8 [ − 2.1, 0.5] mmHg) in the subgroup aged &lt;65 years. These changes were −14.6/−7.2 and −11.5/−6.7 (−3.0 [−4.9, −1.2]/−0.5 [−1.5, 0.5] mmHg) in the subgroup aged ≥65 years. The incidences of serum potassium level ≥5.5 mEq/L were 2.2% and 1.9% in the esaxerenone-treated subgroups aged &lt;65 and ≥65 years, respectively. In conclusion, esaxerenone achieved the pre-defined non-inferiority margin to trichlormethiazide in its BP-lowering effect regardless of age. In patients aged &lt;65 years, esaxerenone achieved the non-inferiority margin to trichlormethiazide in lowering both SBP and DBP. In patients aged ≥65 years, esaxerenone was superior to trichlormethiazide in lowering SBP and achieved the&#xa0;non-inferiority margin to trichlormethiazide in lowering DBP. The impact of esaxerenone on serum potassium levels did not show a specific age-related effect.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Home blood pressure-lowering effect of esaxerenone vs trichlormethiazide for uncontrolled hypertension: a prespecified subanalysis of the EXCITE-HT randomized controlled study by age subgroup

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月28日

查看全文
  • Kazuomi Kario,
  • Hiroyuki Ohbayashi,
  • Masami Hashimoto,
  • Naoki Itabashi,
  • Mitsutoshi Kato,
  • Kazuaki Uchiyama,
  • Kunio Hirano,
  • Noriko Nakamura,
  • Takahide Miyamoto,
  • Hirotaka Nagashima,
  • Hidenori Ishida,
  • Yusuke Ebe,
  • Tsuguru Hatta,
  • Toshiki Fukui,
  • Tomohiro Katsuya,
  • Tatsuo Shimosawa,
  • Takashi Taguchi,
  • Ayumi Tanabe,
  • Mitsuru Ohishi

摘要

This predefined subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to determine whether the comparative efficacy and safety of esaxerenone and trichlormethiazide differs with age. Patients were divided into two age subgroups (<65 and ≥65 years). The non-inferiority of esaxerenone to trichlormethiazide was assessed based on the upper limit of the two-sided 95% confidence interval (CI) for the difference in systolic/diastolic blood pressure (SBP/DBP) changes. Esaxerenone was considered non-inferior if this value was <3.9/ < 2.1 mmHg; if it was <0 mmHg, esaxerenone was considered superior in its BP-lowering effect. The results showed that the least squares mean changes in morning home SBP/DBP from baseline to the end of treatment (primary endpoint) were −9.5/−5.7 with esaxerenone and −8.2/−4.9 mmHg with trichloromethiazide (between-group difference: −1.3 [95% CI, −3.3, 0.8]/−0.8 [ − 2.1, 0.5] mmHg) in the subgroup aged <65 years. These changes were −14.6/−7.2 and −11.5/−6.7 (−3.0 [−4.9, −1.2]/−0.5 [−1.5, 0.5] mmHg) in the subgroup aged ≥65 years. The incidences of serum potassium level ≥5.5 mEq/L were 2.2% and 1.9% in the esaxerenone-treated subgroups aged <65 and ≥65 years, respectively. In conclusion, esaxerenone achieved the pre-defined non-inferiority margin to trichlormethiazide in its BP-lowering effect regardless of age. In patients aged <65 years, esaxerenone achieved the non-inferiority margin to trichlormethiazide in lowering both SBP and DBP. In patients aged ≥65 years, esaxerenone was superior to trichlormethiazide in lowering SBP and achieved the non-inferiority margin to trichlormethiazide in lowering DBP. The impact of esaxerenone on serum potassium levels did not show a specific age-related effect.